{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:11:55Z","timestamp":1788455515979,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Vivian Allison and Daniel J. Pachman Fund","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}]},{"name":"The Vivian Allison and Daniel J. Pachman Fund","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}]},{"name":"The DenUyl Family Fund","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}]},{"name":"The DenUyl Family Fund","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}]},{"name":"Cure JM Foundation","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}]},{"name":"Cure JM Foundation","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}]},{"name":"Children\u2019s Health of Orange County (CHOC) Chief Scientific Officer (CSO) Award","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}]},{"name":"Children\u2019s Health of Orange County (CHOC) Chief Scientific Officer (CSO) Award","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umm Al-Qura University","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}]},{"name":"Umm Al-Qura University","award":["22UQU4300201DSR07"],"award-info":[{"award-number":["22UQU4300201DSR07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Objective: This study determined if an accessible, serologic indicator of vascular disease activity, the von Willebrand factor antigen (vWF:Ag), was useful to assess disease activity in children with juvenile dermatomyositis (JDM), a rare disease, but the most common of the pediatric inflammatory myopathies. Methods: A total of 305 children, median age 10 years, 72.5% female, 76.5% white, with definite\/probable JDM at diagnosis, were enrolled in the Ann &amp; Robert H. Lurie Cure JM Juvenile Myositis Repository, a longitudinal database. Disease Activity Score (DAS) and vWF:Ag data were obtained at each visit. These data were analyzed using generalized estimating equation (GEE) models (both linear and logistic) to determine if vWF:Ag reflects disease severity in children with JDM. A secondary analysis was performed for untreated active JDM to exclude the effect of medications on vWF:Ag. Result: The vWF:Ag test was elevated in 25% of untreated JDM. We found that patients with elevated vWF:Ag had a 2.55-fold higher DAS total (CI95: 1.83\u20133.27, p &lt; 0.001). Patients with difficulty swallowing had 2.57 higher odds of elevated vWF:Ag (CI95: 1.5\u20134.38, p &lt; 0.001); those with more generalized skin involvement had 2.58-fold higher odds of elevated vWF:Ag (CI95: 1.27\u20135.23, p = 0.006); and those with eyelid peripheral blood vessel dilation had 1.32-fold higher odds of elevated vWF:Ag (CI95: 1.01\u20131.72, p = 0.036). Untreated JDM with elevated vWF:Ag had more muscle weakness and higher muscle enzymes, neopterin and erythrocyte sedimentation rate compared to JDM patients with a normal vWF:Ag. Conclusion: vWF:Ag elevation is a widely accessible concomitant of active disease in 25% of JDM.<\/jats:p>","DOI":"10.3390\/biomedicines11020552","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T03:41:17Z","timestamp":1676346077000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-8437","authenticated-orcid":false,"given":"Ellie","family":"Gibbs","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Wellesley College, Wellesley, MA 02481, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-4863","authenticated-orcid":false,"given":"Amer","family":"Khojah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, Umm Al-Qura University, Makkah 21421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-7112","authenticated-orcid":false,"given":"Gabrielle","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Cure-JM Center of Excellence in Juvenile Myositis Research and Care, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1369-7954","authenticated-orcid":false,"given":"Louis","family":"Ehwerhemuepha","sequence":"additional","affiliation":[{"name":"Computational Research, Children\u2019s Hospital of Orange County Research Institute, Orange, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-574X","authenticated-orcid":false,"given":"Lauren M.","family":"Pachman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Cure-JM Center of Excellence in Juvenile Myositis Research and Care, Chicago, IL 60611, USA"},{"name":"Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995-1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: A novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpeds.2017.12.053","article-title":"Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity","volume":"195","author":"Pachman","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3899\/jrheum.160024","article-title":"Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis","volume":"43","author":"Cao","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J. Autoimmun"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile Dermatomyositis-Clinical Phenotypes","volume":"21","author":"Li","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5114\/reum.2022.119045","article-title":"Clinical and autoantibody phenotypes of juvenile dermatomyositis","volume":"60","author":"Boyarchuk","year":"2022","journal-title":"Reumatologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00296-019-04442-1","article-title":"Macrophage activation syndrome in juvenile dermatomyositis: A systematic review","volume":"40","author":"Poddighe","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_10","first-page":"6497357","article-title":"Pneumatosis Intestinalis Associated with Juvenile Dermatomyositis","volume":"2016","author":"Miyamae","year":"2016","journal-title":"Case Rep. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e000385","DOI":"10.1136\/rmdopen-2016-000385","article-title":"Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: A clue to disease activity","volume":"3","author":"Briones","year":"2017","journal-title":"RMD Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.10924","article-title":"Disease activity score for children with juvenile dermatomyositis: Reliability and validity evidence","volume":"49","author":"Bode","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","article-title":"New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1136\/annrheumdis-2017-212786","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"77","author":"Lundberg","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.20179","article-title":"Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies","volume":"50","author":"Huber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.181275","article-title":"Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis","volume":"47","author":"Kishi","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_18","first-page":"739","article-title":"Monitoring disease activity in juvenile dermatomyositis: The role of von Willebrand factor and muscle enzymes","volume":"21","author":"Guzman","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3414\/ME10-01-0026","article-title":"Generalized estimating equations. Notes on the choice of the working correlation matrix","volume":"49","author":"Ziegler","year":"2010","journal-title":"Methods Inf. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hardin, J.W., and Joseph, M. (2002). Generalized Estimating Equations, Chapman and Hall\/CRC.","DOI":"10.1201\/9781420035285"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1537-2995.2004.03338.x","article-title":"ABO and Rh(D) phenotype frequencies of different racial\/ethnic groups in the United States","volume":"44","author":"Garratty","year":"2004","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Khojah, A., Morgan, G., and Pachman, L.M. (2021). Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010008"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.141474","article-title":"MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis","volume":"43","author":"Xu","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41598-021-04302-8","article-title":"Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive","volume":"12","author":"Roberson","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/ndt\/gfu379","article-title":"Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"30","author":"Salmela","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/kes156","article-title":"von Willebrand factor antigen--a possible biomarker of disease activity in childhood central nervous system vasculitis?","volume":"51","author":"Cellucci","year":"2012","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00467-017-3597-4","article-title":"Vasculitis update: Pathogenesis and biomarkers","volume":"33","author":"Brogan","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2018-02-769000","article-title":"Inflammation, von Willebrand factor, and ADAMTS13","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10238-021-00769-x","article-title":"High levels of Von Willebrand factor markers in COVID-19: A systematic review and meta-analysis","volume":"22","author":"Rostami","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.25806","article-title":"von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis","volume":"56","author":"Ferlitsch","year":"2012","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1177\/2050640618779660","article-title":"von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C","volume":"6","author":"Takaya","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"Willebrand factor, endothelial dysfunction, and cardiovascular disease","volume":"4","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5620314","DOI":"10.1155\/2017\/5620314","article-title":"The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy","volume":"2017","author":"Gragnano","year":"2017","journal-title":"Mediators Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/acr.24535","article-title":"Association of p155\/140 Autoantibody With Loss of Nailfold Capillaries but not Generalized Lipodystrophy: A Study of Ninety-Six Children With Juvenile Dermatomyositis","volume":"74","author":"Khojah","year":"2022","journal-title":"Arthritis Care Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40674-020-00168-5","article-title":"Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy","volume":"7","author":"Pachman","year":"2021","journal-title":"Curr. Treatm. Opt. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","article-title":"Duration of illness is an important variable for untreated children with juvenile dermatomyositis","volume":"148","author":"Pachman","year":"2006","journal-title":"J. Pediatr."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/2\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:34:41Z","timestamp":1760121281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/2\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["biomedicines11020552"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11020552","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}